TY - JOUR
T1 - ERS International Congress 2021
T2 - highlights from the Pulmonary Vascular Diseases Assembly
AU - Lichtblau, Mona
AU - Piccari, Lucilla
AU - Ramjug, Sheila
AU - Bokan, Aleksandar
AU - Lechartier, Benoit
AU - Jutant, Etienne Marie
AU - Barata, Margarida
AU - Garcia, Agustin Roberto
AU - Howard, Luke S.
AU - Adir, Yochai
AU - Delcroix, Marion
AU - Jara-Palomares, Luis
AU - Bertoletti, Laurent
AU - Sitbon, Olivier
AU - Ulrich, Silvia
AU - Noordegraaf, Anton Vonk
N1 - Publisher Copyright:
© The authors 2022.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - This article aims to summarise the latest research presented at the virtual 2021 European Respiratory Society (ERS) International Congress in the field of pulmonary vascular disease. In light of the current guidelines and proceedings, knowledge gaps are addressed and the newest findings of the various forms of pulmonary hypertension as well as key points on pulmonary embolism are discussed. Despite the comprehensive coverage of the guidelines for pulmonary embolism at previous conferences, discussions about controversies in the diagnosis and treatment of this condition in specific cases were debated and are addressed in the first section of this article. We then report on an interesting pro–con debate about the current classification of pulmonary hypertension. We further report on presentations on Group 3 pulmonary hypertension, with research exploring pathogenesis, phenotyping, diagnosis and treatment; important contributions on the diagnosis of post-capillary pulmonary hypertension are also included. Finally, we summarise the latest evidence presented on pulmonary vascular disease and COVID-19 and a statement on the new imaging guidelines for pulmonary vascular disease from the Fleischner Society.
AB - This article aims to summarise the latest research presented at the virtual 2021 European Respiratory Society (ERS) International Congress in the field of pulmonary vascular disease. In light of the current guidelines and proceedings, knowledge gaps are addressed and the newest findings of the various forms of pulmonary hypertension as well as key points on pulmonary embolism are discussed. Despite the comprehensive coverage of the guidelines for pulmonary embolism at previous conferences, discussions about controversies in the diagnosis and treatment of this condition in specific cases were debated and are addressed in the first section of this article. We then report on an interesting pro–con debate about the current classification of pulmonary hypertension. We further report on presentations on Group 3 pulmonary hypertension, with research exploring pathogenesis, phenotyping, diagnosis and treatment; important contributions on the diagnosis of post-capillary pulmonary hypertension are also included. Finally, we summarise the latest evidence presented on pulmonary vascular disease and COVID-19 and a statement on the new imaging guidelines for pulmonary vascular disease from the Fleischner Society.
UR - http://www.scopus.com/inward/record.url?scp=85131159961&partnerID=8YFLogxK
U2 - 10.1183/23120541.00665-2021
DO - 10.1183/23120541.00665-2021
M3 - Article
AN - SCOPUS:85131159961
SN - 2312-0541
VL - 8
JO - ERJ Open Research
JF - ERJ Open Research
IS - 2
M1 - 00665-2021
ER -